参青方对三硝基苯磺酸诱导结肠炎大鼠结肠SP和VIP表达的影响  

Effect of Shenqing recipe on the expression of substance P and vasoactive intestine poiypeptide in TNBS-induced rat colitis

作　　者：戴彦成[1] 唐志鹏[1] 王臻楠[1] 张亚利[1] 李凯[1] 何新颖[1] 

机构地区：[1]上海中医药大学附属龙华医院消化内科上海中医药大学脾胃病研究所,上海市200032

出　　处：《世界华人消化杂志》2009年第3期253-258,共6页World Chinese Journal of Digestology

基　　金：上海市科学技术委员会科研基金资助项目;No.06411941;上海市教育委员会重点学科资助项目;No.J50305~~

摘　　要：目的:探讨三硝基苯磺酸(TNBS)诱导结肠炎大肠道动力学异常的发病机制,研究参青方消炎愈溃,以及调节结肠神经递质P物质(SP)、血管活性肠肽(VIP)的作用机制.方法:用TNBS复制实验性大鼠结肠炎模型,随机分为参青方高剂量组、参青方低剂量组、美沙拉嗪组、模型Ⅰ组、模型Ⅱ组及正常组,每组各10只.其中模型Ⅰ组于造模3d时处死,其余5组均在3d开始给药,每日1次,连续给药7d时处死.取大鼠结肠病变部位标本,检测结肠组织中超氧化物歧化酶(SOD)、髓过氧化物酶(MPO)及丙二醛(MDA)含量;免疫组化染色法检测SP和VIP的表达.结果:模型Ⅰ组结肠黏膜MPO、MDA含量比正常组增加(2.78±0.26 vs 0.56±0.20,15.14±2.02 vs 7.41±1.19,均P<0.05),SOD含量减少(84.15±6.27 vs 176.33±12.06,P<0.05);与模型Ⅱ组比较,参青方高剂量组、参青方低剂量组和美沙拉嗪组MPO、MDA含量明显减少(1.03±0.23,1.57±0.27,1.59±0.12 vs 2.03±0.33;8.30±1.27,10.09±1.09,10.46±1.37 vs 14.38±1.84,均P<0.05),SOD含量增加(190.17±7.71,178.90±8.59,176.13±9.50 vs 107.09±6.37,均P<0.05).正常组大鼠结肠组织可见VIP、SP阳性表达,与正常组比较,模型Ⅰ组大鼠结肠组织SP、VIP表达减少(42608.00±4823.37 vs 461570.00±18227.7;50801.90±7698.09 vs 607333.90±34166.35,均P<0.05),经治疗后,参青方高剂量组、参青方低剂量组和美沙拉嗪组SP、VIP表达上调(302253.10±11484.92,171014.7±21993.34,158355.10±13855.66 vs 77260.26±9375.49;419171.36±23267.98,279572.17±26645.82,282438.50±13236.13 vs 111838.85±9698.09,均P<0.05).结论:参青方能够上调结肠VIP和SP表达,因而具有调节肠道动力学的作用.AIM： To study the change of intestinal motility in trinitrobenzene sulfonic acid （TNBS）-induced rat colitis and to investigate the mechanism underlying the anti-inflammatory action and regulating the expression of substance P（SP）and vasoactive intestinal Polypeptide （VIP） by Shenqing recipe （SQR）. METHODS： Rats were randomly divided into SQR high dose group, SQR low dose group,5- ASA group, model Ⅰ group, model Ⅱgroup and normal group with 10 rats in each group. Rats in model Ⅰ group were killed on day 3, and rats in the other groups were given medicine on day 3, once a day for 7 days. Rats were killed after 7 days＇ treatment. Histopathological assessment of the colonic mucosa was performed. MPO, MDA and SOD levels in the colonic mucosa were determined by ultraviolet spectrometer. The expression of neurotransmitters including SP and VIP was detected by immunohistochemical staining. RESULTS： Compared with the normal group, the colonic mucosal levels of MPO and MDA were increased （2.78 ± 0.26 vs 0.56 ± 0.20, 15.14 ± 2.02 vs 7.41 ± 1.19, P 〈 0.05）, while the level of SOD was decreased in the model Ⅰ group （84.15 ± 6.27 vs 176.33 ± 12.06, P 〈 0.05）. Compared with model Ⅱ group, the colonic mucosa levels of MPO and MDA were markedly decreased （1.03 ± 0.23, 1.57 ± 0.27, 1.59 ± 0.12 vs 2.03 ± 0.33; 8.30 ± 1.27,10.09 ± 1.09, 10.46 ± 1.37 vs 14.38 ± 1.84, P 〈 0.05）, and the level of SOD was increased in the SQR high dose group, SQR low dose group and 5-ASA group （190.17 ± 7.71, 178.90 ± 8.59, 176.13 ± 9.50 vs 107.09 ± 6.37, P 〈 0.05）. Compared with the normal group, the expression of VIP and SP of the colonic mucosal was decreased in model Ⅰ group （42 608.00 ± 4823.37 vs 461 570.00 ± 18 227.7; 50 801.90 ± 7698.09 vs 607 333.90 ± 34 166.35, P 〈 0.05）. After treatment, compared with the model Ⅱ group ,the expressions of VIP and SP were up-regulated in SQR high dose group, SQR low dose group and 5-ASA group （302 253.10 ± 11 484.92,

关 键 词：参青方 三硝基苯磺酸 结肠炎 肠道动力学 P物质 血管活性肠肽 

分 类 号：R285.5[医药卫生—中药学]